ASEAN Heart Journal

Intended for healthcare professional

Original Paper

ASEAN Heart Journal

April 2014, 22:3

First online: 05 December 2014

Original Paper

New Oral Anticoagulants

Chee Yen Lin 1
Open Access
This content is freely available to anyone, anywhere at any time.
  • Summary
  • Supplementary Material
  • References
  • About this Article

Abstract

Background:
The approval of the new target specific oral anticoagulants provides clinicians with alternatives to warfarin. This review focuses on dabigatran, a direct thrombin inhibitor and rivaroxavan, a direct factor Xa inhibitor. These new oral anticoagulants have favourable pharmacological properties that overcome many of the problems associated with warfarin use. Their efficacy and safety have also been shown in large Phase III randomized studies in VTE prevention in major orthopedic surgery, treatment of acute VTE and prevention of stroke and systemic embolism in atrial fibrillation. Although bleeding is an anticipated side effect, this risk can be prevented or minimized by appropriate prescribing. Specifically, the oral new anticoagulants should only be used within licensed indications, clinicians should have basic knowledge of their pharmacological properties, particularly their dependence on renal clearance and restrict eligible patients to those with a similar profile as patients included in the original studies. The management of life-threatening bleeding is presently empirical due to the lack of good quality data and specific reversal antidotes are not currently available. All hospitals should develop clinical practice guidelines and have systems in place to ensure the safe and appropriate use of these new anticoagulants.

Keywords
Warfarin - Enoxaparin - Dabigatran - Major Bleeding - Rivaroxaban


Chee Yen Lin
National University Hospital, Singapore
Correspondence to Yen Lin CHEE, National University Hospital, Singapore.
Telephone: (+65) 6779 5555
E-mail: Yen Lin CHEE <[email protected]

Open Access: This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Supplementary Material

Nil

 

References

1. http://eservice.hsa.gov.sg/prism/common/enquirepublic/SearchDRBProduct.do?action=load  (accessed 10 March 2014).

2. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S–16S. CrossRef

3. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005 Dec;61(12):873-80. Epub 2005 Nov 17. PubMed     CrossRef

4. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm  (accessed 10 March 2014).

5. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep;126(3):175–82. doi: 10.1016/j. thromres.2010.03.021. Epub 2010 May 15. PubMed  CrossRef

6. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011 Mar;105(3):444–53. doi: 10.1160/TH10-09-0601. Epub 2010 Dec 6. PubMed   CrossRef

7. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20;11(1):21. PubMed  CrossRef

8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–51. PubMed   CrossRef

9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–91. PubMed   CrossRef ​

10. Ng HJ, Chee YL, Ponnudurai K, Lim LC, Tan D, Tay JC, Handa PK, Akbar Ali M, Lee LH. Consensus recommendations for preventing and PubMed

11. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010 Apr;49(4):259–68. PubMed   CrossRef

About this Article

Title
New Oral Anticoagulants


Open Access
Available under Open Access


Journal >> 22:1


Online Date
21 November 2019


DOI
10.7603/s40602-014-0002-4


Online ISSN
2315-4551


Publisher
ASEAN Federation of Cardiology


Additional Links Cardiology


Keywords
Enoxaparin
Warfarin
Enoxaparin
Dabigatran
Major Bleeding
Rivaroxaban


Author Affiliations
1. National University Hospital, Singapore, Singapore


Correspondence to:
Chee Yen Lin, [email protected]